Cathie Wood Doubles Down on Biotech as 2025 Ends, Offloads Rocket Lab

This article first appeared on GuruFocus.

Cathie Wood’s ARK Invest made a series of end-of-year portfolio adjustments on the second final trading day of 2025, tilting further toward biotechnology while easing exposure to several growth names.

The largest purchase was Intellia Therapeutics (NASDAQ:NTLA). ARK picked up more than 145,000 shares, a position valued at roughly $1.3 million, adding to its exposure to gene-editing companies heading into the new year.

The firm also increased its stake in Twist Bioscience (NASDAQ:TWST), buying just over 50,000 shares across its flagship innovation and genomics ETFs. The move, totaling about $1.7 million, highlights continued interest in synthetic biology and DNA-based research tools.

Other biotech additions included Beam Therapeutics (NASDAQ:BEAM), where ARK added more than 46,000 shares, and Pacific Biosciences of California (NASDAQ:PACB), with purchases exceeding 423,000 shares. ARK also made a smaller investment in Kodiak AI (NASDAQ:KDK).

On the sell side, ARK trimmed Rocket Lab (NASDAQ:RKLB), unloading about 1,545 shares in a modest reduction that fits a recent pattern. The firm also scaled back positions in Roku (ROKU), Shopify (SHOP), and Ionis Pharmaceuticals (NASDAQ:IONS), signaling portfolio fine-tuning rather than wholesale exits.